A randomized study of KRAS-guided maintenance therapy with bevacizumab, erlotinib or metronomic capecitabine after first-line induction treatment of metastatic colorectal cancer: the Nordic ACT2 trial.
暂无分享，去创建一个
M. Albertsson | E. Fernebro | J. Frödin | L. Vestermark | L. Vestermark | A. Johnsson | H. Hagman | J. Sundberg | A. Berglund | M. Albertsson | Å. Berglund | Anders Johnsson